Tekla Capital Management’s Immunogen Inc IMGN Stock Holding History

Tekla Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-168,190	Closed	-$1.08M	–	220
2020 Q4	$1.08M	Hold	168,190	–	–	0.04%	175
2020 Q3	$605K	Hold	168,190	–	–	0.02%	192
2020 Q2	$774K	Hold	168,190	–	–	0.03%	203
2020 Q1	$574K	Hold	168,190	–	–	0.03%	191
2019 Q4	$859K	Hold	168,190	–	–	0.03%	181
2019 Q3	$407K	Hold	168,190	–	–	0.02%	175
2019 Q2	$365K	Hold	168,190	–	–	0.01%	187
2019 Q1	$456K	Hold	168,190	–	–	0.02%	181
2018 Q4	$807K	Hold	168,190	–	–	0.03%	171
2018 Q3	$1.59M	Buy	+168,190	New	+$1.62M	0.06%	166
2013 Q3	–	Sell	-393,773	Closed	-$6.53M	–	65
2013 Q2	$6.53M	Buy	+393,773	New	+$6.38M	0.89%	33

Other funds holding IMGN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Tekla Capital Management's IMGN Position: Q1 2021 in Review

Tekla Capital Management sold out of Immunogen Inc (IMGN) in Q1 2021, closing a stake of 168,190 shares — an estimated $1.08M sold.

Tekla Capital Management first reported a position in IMGN in Q2 2013 and held it in 11 quarters. The position peaked at $6.53M in Q2 2013. 217 funds tracked by Wall St. Rank hold IMGN as of Q1 2021.

Tekla Capital Management reported no remaining Immunogen Inc position as of Q1 2021 after selling out during the quarter.
Tekla Capital Management sold 168,190 Immunogen Inc shares in Q1 2021, an estimated $1.08M.
Tekla Capital Management first reported a position in Immunogen Inc in Q2 2013 and held it in 11 quarters.
Tekla Capital Management's Immunogen Inc position peaked at $6.53M in Q2 2013.
217 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.